Literature DB >> 29453001

Transmitral Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy.

Brody Wehman1, Mehrdad Ghoreishi1, Nathaniel Foster1, Libin Wang2, Michael N D'Ambra1, Nathan Maassel1, Sam Maghami1, Rachael Quinn1, Murtaza Dawood1, Stacy Fisher2, James S Gammie3.   

Abstract

BACKGROUND: Intrinsic abnormalities of the mitral valve are common in patients with hypertrophic cardiomyopathy and may need to be addressed at operation.
METHODS: Consecutive patients undergoing transmitral septal myectomy were retrospectively reviewed. The ventricular septum was exposed through a left atriotomy, and the anterior leaflet of the mitral valve was detached from its annulus. An extended myectomy was performed to the base of the papillary muscles. After myectomy, the anterior leaflet was reattached and concomitant mitral valve repair or replacement was performed. In some cases, we performed a modified anterolateral commissural closure suture, which served to reposition the lateral aspect of the anterior leaflet out of the left ventricular outflow tract ("curtain stitch").
RESULTS: Twenty patients who underwent this procedure were identified (70% women; mean age 63 years). Mitral regurgitation was moderate in 55% and severe in 40%. Preoperative peak left ventricular outflow tract gradient was 92 ± 43 mm Hg. Mitral valve repair (n = 11) or replacement (n = 9) was performed. Predischarge transthoracic echocardiography demonstrated a left ventricular outflow tract gradient of 10 ± 5 mm Hg. There was no operative mortality. Follow-up was 100% complete and averaged 22 ± 25 months. No patient required reoperation, and there was no recurrence of left ventricular outflow tract obstruction or mitral regurgitation greater than mild.
CONCLUSIONS: Potential advantages of transmitral myectomy include a panoramic view of the septum and mitral subvalvular apparatus and the ability to simultaneously address mitral valve pathology. Consideration should be given to using the transmitral approach to septal myectomy as the preferred approach for the surgical treatment of hypertrophic cardiomyopathy.
Copyright © 2018 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29453001     DOI: 10.1016/j.athoracsur.2017.10.045

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

Review 1.  Review of Contemporary Invasive Treatment Approaches and Critical Appraisal of Guidelines on Hypertrophic Obstructive Cardiomyopathy: State-of-the-Art Review.

Authors:  Steven Lebowitz; Mariusz Kowalewski; Giuseppe Maria Raffa; Danny Chu; Matteo Greco; Caterina Gandolfo; Carmelo Mignosa; Roberto Lorusso; Piotr Suwalski; Michele Pilato
Journal:  J Clin Med       Date:  2022-06-14       Impact factor: 4.964

2.  Transaortic Shallow Septal Myectomy and Cutting of Secondary Fibrotic Mitral Valve Chordae-A 5-Year Single-Center Experience in the Treatment of Hypertrophic Obstructive Cardiomyopathy.

Authors:  Lucian Florin Dorobantu; Toma Andrei Iosifescu; Razvan Ticulescu; Maria Greavu; Maria Alexandrescu; Andrei Dermengiu; Miruna Mihaela Micheu; Monica Trofin
Journal:  J Clin Med       Date:  2022-05-30       Impact factor: 4.964

3.  Thoracoscopic Trans-mitral Septal Myectomy for Hypertrophic Obstructive Cardiomyopathy in the Elderly.

Authors:  Peijian Wei; Jian Liu; Jiexu Ma; Yanjun Liu; Tong Tan; Hongxiang Wu; Wei Zhu; Zhao Chen; Jimei Chen; Jian Zhuang; Huiming Guo
Journal:  Front Cardiovasc Med       Date:  2022-03-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.